Actively Recruiting
PEP-buddy in COPD: Effect on Dyspnea Severity and Mechanism of Action
Led by University Medical Center Groningen · Updated on 2026-04-24
25
Participants Needed
1
Research Sites
152 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Chronic dyspnea is the most characteristic symptom of patients with Chronic Obstructive Pulmonary Disease (COPD), with intermittent increases during exercise and other events.Despite optimal standard therapy, episodic dyspnea is a common occurrence in COPD. Recently, the PEP buddy was developed which is an easy-to use, hands-free device that generates positive expiratory pressure (PEP). Although currently the available evidence is limited, it indicates that utilizing the PEP-buddy can result in enhancements in dyspnea during exertion, exertional desaturation and overall quality of life. More research is needed to evaluate the effectiveness of this device and the long term usability, as well as getting more insight in the mechanism of action. Therefore, the aim of our study is to explore the potential of this device for patients with COPD and episodic breathlessness.
CONDITIONS
Official Title
PEP-buddy in COPD: Effect on Dyspnea Severity and Mechanism of Action
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 40 years or older
- Read, understood and signed Informed Consent
- COPD Gold class II-IV/ B or E (FEV1 less than 60% of predicted, CAT 10 points or higher)
- Optimized standard therapy according to the study physician
- Episodic breathlessness requiring intervention at least three days per week
You will not qualify if you...
- Other severe disease causing episodic breathlessness
- Life expectancy 3 months or less
- COPD exacerbation within 4 weeks prior to inclusion
- Change in COPD management targeting breathlessness within 8 weeks prior to inclusion
- Inability to use the PEP buddy device
- Currently participating in another interventional clinical study
- Any other condition that the investigator believes makes the patient unsuitable or interferes with study participation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
UMCG
Groningen, Provincie Groningen, Netherlands, 9700 RB
Actively Recruiting
Research Team
J
Jorine Hartman, PhD
CONTACT
M
Marlies van Dijk, MD PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here